Tag Archives: liver metastases

Treating Liver Metastases Webinar Available Online

On Monday, May 16th, 2011, Dr. Andrew Kennedy, a well-known researcher in liver metastases, led a Fight Colorectal Cancer webinar discussing an issue that affects thousands of colorectal cancer patients. Colorectal cancer often metastasizes first to the liver, so learning how to manage growth of those tumors can help with patient survival.   Treatment of liver mets has come a long way in the last two decades. You can learn about these developments in an archive of the webinar below. Our thanks to Dr. Andrew Kennedy for leading the discussion. His extensive knowledge of this issue is highly respected in the field of radiology. He graciously donated his time to bring

Upcoming Patient Webinars Will Bring the Science to YOU

Fight Colorectal Cancer is giving you the opportunity to talk to researchers and medical professionals in April and May through online webinars designed to bring the science of treating colorectal cancer down to the personal. The latest news from the petri dish Wednesday, April 20, 2011 8 – 9 PM Eastern Dr. Rona Yaeger will discuss the research she has been conducting over the past year with the grant she received as part of Fight Colorectal Cancer’s Lisa Fund research program. Dr. Yaeger’s research focused on inhibiting the AKT pathway in colorectal cancer cells. She conducted basic research to determine how inhibitors to the pathway might affect cells of patients

KRAS Mutations Match in Almost All Tumors

If there is a KRAS mutation in the primary colon or rectal tumor, there is almost always a matching mutation when that tumor spreads to the liver. Researchers in the Netherlands tested both tumors for KRAS mutations in over 300 patients whose cancer had spread to their livers. They found about a third of patients had KRAS mutations and KRAS status matched in 96 percent of the cases, making it possible to test either tumor to make decisions about treatment with Erbitux® (cetuximab) or Vectibix® (panitumumab)

Clinical Trial at NIH for Unresectable Liver Tumors

Patients with liver tumors, including those that have spread from colorectal cancer, can enroll in a clinical trial at the National Institutes of Health Clinical Center in Bethesda. The trial will test the effectiveness of infusing the drug melphalan through the artery that feeds the liver. Colorectal cancer patients with liver metastases are eligible for the trial if they have already had chemotherapy including irinotecan or oxaliplatin.  Limited cancer outside of the liver is acceptable if the most serious problem is within the liver itself.

Young Patients Do Worse After Surgery for Liver Mets

Patients under 40 appear to have more aggressive liver tumors from colorectal cancer and poorer long-term outcomes. After surgery to remove the cancer that had spread to their liver, patients who were 40 or younger had poorer overall survival and shorter time until cancer returned. The percentage of younger patients who were alive without cancer five years later was similar to older patients, which the research team attributed to more aggressive treatment for the young patients, along with repeated surgery. 

C3 Advocates Contribute to RFA Effectiveness Review

How useful is radiofrequency ablation (RFA) in treating liver metastases from colorectal cancer? To answer that question, American Society for Clinical Oncology scientists included two C3 advocates, Rob Michelson and Dr. Andrew Guisti, on an expert panel looking at published RFA research. In appreciation, the panel dedicated their Clinical Evidence Review to Michelson who died in January, 2008. The Expert Panel wishes to dedicate this Clinical Evidence Review to Rob Michelson, who served as the patient representative at the Panel meeting in October 2007 and passed away early in 2008. His contributions at the meeting and as a reviewer of the first draft were substantive and thought provoking.

Talking to Your Doctor about Liver Mets

What should you and your doctor talk about if your colon or rectal cancer has spread to your liver? Deciding on the best way to manage liver metastases from colorectal cancer isn’t easy. It’s best done with the involvement of  multidisciplinary team of doctors and thoughtful discussion with the patient. In developing the ASCO 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer, the Expert Panel developed points for patients and physicians to consider during an office visit to learn about treatment options.

Patient Outcomes Vary Depending on Liver Resectability

Patients with stage IV colorectal cancer live longer when tumors in their liver can be removed surgically, but not all patients have cancer that can be operated on. Separating patients with liver tumors from colorectal cancer into three groups according to possible liver resectability, British doctors found a wide variation in both overall survival and progression-free survival three years later.

Erbitux Plus Chemo Can Make Liver Mets Surgery Possible

Chemotherapy and Erbitux® (cetuximab) reduced liver tumors from colorectal cancer enough for patients to have them removed surgically. Although their cancer was initially too extensive to be surgically removed (resected) chemotherapy combined with Erbitux allowed about a third of patients to have surgery that completely removed all visible signs of liver tumors.  Tumor shrinkage occured in about two out of three patients, despite which chemotherapy was used.

Liver Symposium Coming to Denver

The Liver Symposium: Embracing Excellence in the Treatment of Hepatic Tumors will be held at the Denver Marriott Tech Center on Saturday, August 22, 2009 from 8 a.m. to 5 p.m. Directed at both health professionals and patients, the Liver Symposium is unique in combining information about liver tumors from medical experts and cancer survivors.